e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 50

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Hamzah Abu‐Sbeih; Cynthia N. Tran; Phillip S. Ge; Manoop S. Bhutani; Mazen Alasadi; Aung Naing; Amir A. Jazaeri; Yinghong Wang · 2019 · Journal for ImmunoTherapy of Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune-mediated adverse events can complicate ICI treatment. Acute cholecystitis in patients receiving ICI therapy has not been characterized. We aimed to describe the clinical features of patients who developed ICI-related cholecystitis. METHODS: We evaluated a case series of patients at a tertiary cancer center who received ICI therapy and developed cholecystitis, diagnosed by clinical presentation and diagnostic imaging, during 2010-2018. Patients with a history of chronic cholecystitis

Abstract by Hamzah Abu‐Sbeih; Cynthia N. Tran; Phillip S. Ge; Manoop S. Bhutani; Mazen Alasadi; Aung Naing; Amir A. Jazaeri; Yinghong Wang, Journal for ImmunoTherapy of Cancer (2019) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1186/s40425-019-0604-2